Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study

Eun, Hee Chul; Kwon, Oh Sang; Yeon, Je Ho; Shin, Hyungcheol; Kim, Byung Yoon; Ro, Byung In; Cho, Han Kyong; Sim, Woo Young; Lew, Bark Lynn; Lee, Won‐Soo; Park, Hwa Young; Hong, Soon-Tae; Ji, Jae Hong

doi:10.1016/j.jaad.2009.09.018

Cited by 113 publications

(86 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sexual AE were the most commonly reported treatment‐related AE across studies of dutasteride for male AGA 5, 6, 7, 8. However, most events were mild, occurred early and resolved during continuing treatment or upon treatment cessation 6.…”

Section: Discussionmentioning

confidence: 99%

“…However, most events were mild, occurred early and resolved during continuing treatment or upon treatment cessation 6. The frequency of sexual AE across studies of 5‐ARI has been inconsistent, with more recent studies (ARI1142635 and ARI114264)8 reporting higher incidences than earlier studies (ARIA20046 and ALO106377) 7. Some variation may be attributed to different coding of events or how AE were elicited.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

Tsai

Choi

Kim

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Treatment with 5α‐reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and associated treatment discontinuations, in men treated with dutasteride for androgenetic alopecia. Participants were randomized to receive double‐blind dutasteride 0.5 mg or placebo once daily for 24 weeks, followed by open‐label dutasteride 0.5 mg for an additional 24 weeks. Sexual adverse events were followed up until resolution or for up to 24 weeks after the last dose. Overall, 117 men, 23–50 years of age, were randomized. The incidence of sexual adverse events was approximately twofold higher in the dutasteride group (16%) than the placebo group (8%) during the double‐blind period; the overall incidence of sexual adverse events was lower (5%) during the open‐label period. All adverse events were mild to moderate in severity and considered treatment‐related. The adverse events resolved while on study treatment or after the end of treatment and did not lead to treatment discontinuation. A limitation of this study was the small sample size. The sexual adverse events of impotence, decreased libido and ejaculation disorders reported in this study were expected and reversible.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

Tsai

Choi

Kim

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…A six-months phase III study showed tolerability and improvement of hair growth in AGA patients receiving 0.5 mg/day dutasteride [45]. Recently, Chung and coworkers showed that dutasteride for more than 6 years was safe and increased terminal, vellus and total hair count in male AGA patients [47].…”

Section: Dutasteride and The Management Of Agamentioning

confidence: 99%

“…This leads to a 90% reduction of DHT serum levels whereas finasteride reduces only 70% [43]. The firsts short-term studies comparing dutasteride to finasteride emerged at the 2000s [44][45][46]. Olsen et al showed that 24 weeks dutasteride 2.5 mg is more efficient than finasteride 5 mg in men with AGA [44].…”

Section: Dutasteride and The Management Of Agamentioning

confidence: 99%

Androgenic alopecia and dutasteride in hair mesotherapy: A short review

Busanello¹,

Turcatel²

2018

Our Dermatol Online

View full text Add to dashboard Cite

“…Although with few studies published until now, the use of dutasteride appears to be safe and efficacious in the treatment of patients with AGA [94,95].…”

Section: Alpha Reductase Inhibitorsmentioning

confidence: 99%

Androgenetic Alopecia: a Review and Emerging Treatments

Alves¹

2017

CRDOA

View full text Add to dashboard Cite

Androgenetic Alopecia (AGA) is the most common noncicatricial alopecia that leads to the progressive miniaturization of the hair follicle. Scalp terminal hairs are converted into vellus hairs, primarily due to two factors: genetic predisposition and hormonal stimulation.The incidence and prevalence of AGA increases with age. The onset of AGA is gradual, and when this pathology progresses, the anagen phase shortens and the telogen phase remains constant. The shedding area varies from patient to patient and is usually most marked at the vertex in men, while women with AGA generally lose hair diffusely over the crown.Topical minoxidil and oral finasteride (5-alpha-reductase type II inhibitor) are the gold-standard therapies for AGA and are currently the only Food and Drug Administration (FDA)-approved drugs for the treatment of AGA.The currently available treatments for AGA are sometimes perceived as having limited effectiveness; therefore, the identification of new therapies for this pathology is of utmost importance.This article aims to review the pathogenesis, diagnosis of AGA and all the new emerging treatments for this entity in order to prevent its progression and improve the results of this pathology.

show abstract

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study

Cited by 113 publications

References 23 publications

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

Androgenic alopecia and dutasteride in hair mesotherapy: A short review

Androgenetic Alopecia: a Review and Emerging Treatments

Contact Info

Product

Resources

About